Last reviewed · How we verify
filgrastim, TBO-filgrastim or pegfilgrastim
filgrastim, TBO-filgrastim or pegfilgrastim is a Small molecule drug developed by Biologics & Biosimilars Collective Intelligence Consortium. It is currently in Phase 2 development. Also known as: Neupogen, Neulasta, Granix, Zarxio.
At a glance
| Generic name | filgrastim, TBO-filgrastim or pegfilgrastim |
|---|---|
| Also known as | Neupogen, Neulasta, Granix, Zarxio |
| Sponsor | Biologics & Biosimilars Collective Intelligence Consortium |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
- Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- filgrastim, TBO-filgrastim or pegfilgrastim CI brief — competitive landscape report
- filgrastim, TBO-filgrastim or pegfilgrastim updates RSS · CI watch RSS
- Biologics & Biosimilars Collective Intelligence Consortium portfolio CI
Frequently asked questions about filgrastim, TBO-filgrastim or pegfilgrastim
What is filgrastim, TBO-filgrastim or pegfilgrastim?
filgrastim, TBO-filgrastim or pegfilgrastim is a Small molecule drug developed by Biologics & Biosimilars Collective Intelligence Consortium.
Who makes filgrastim, TBO-filgrastim or pegfilgrastim?
filgrastim, TBO-filgrastim or pegfilgrastim is developed by Biologics & Biosimilars Collective Intelligence Consortium (see full Biologics & Biosimilars Collective Intelligence Consortium pipeline at /company/biologics-biosimilars-collective-intelligence-consortium).
Is filgrastim, TBO-filgrastim or pegfilgrastim also known as anything else?
filgrastim, TBO-filgrastim or pegfilgrastim is also known as Neupogen, Neulasta, Granix, Zarxio.
What development phase is filgrastim, TBO-filgrastim or pegfilgrastim in?
filgrastim, TBO-filgrastim or pegfilgrastim is in Phase 2.
Related
- Manufacturer: Biologics & Biosimilars Collective Intelligence Consortium — full pipeline
- Also known as: Neupogen, Neulasta, Granix, Zarxio
- Compare: filgrastim, TBO-filgrastim or pegfilgrastim vs similar drugs
- Pricing: filgrastim, TBO-filgrastim or pegfilgrastim cost, discount & access